Clinical trials sponsored by Women's Cancer Study Group GmbH

Phase breakdown

Conditions studied

Recruiting trials led by Women's Cancer Study Group GmbH

• Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC
  NCT07242352 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 33 locations
• NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
  NCT06081244 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Female · 43 locations
• NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer
  NCT05704829 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 44 locations
• Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment
  NCT07281833 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations

Common questions

How many trials is Women's Cancer Study Group GmbH recruiting for?

Women's Cancer Study Group GmbH is the lead sponsor of 4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.